Over the coming months, the Pulmonary Fibrosis Foundation's 2025 PFF Walk will aim to raise more than $1 million for the fight against PF.

Living with pulmonary fibrosis, columnist Ann Reynoso writes, means no more independent, spontaneous days with enough energy ...

During the dog days of summer, columnist Sam Kirton takes special care to protect himself from medication side effects.

In CORAL, 165 IPF patients were given one of three doses of nalbuphine ER to test its ability to reduce cough frequency after six weeks.

Columnist Sam Kirton, calling the PF world an inclusive community, promotes care for those LGBTQIA+ while appealing to them to donate organs.

Let-7, an established tumor suppressor microRNA, plays a key role in lung tissue repair and the development of scarring, a ...

A Phase 2 clinical trial has begun recruiting that’s assessing the safety and efficacy of LTI-03, Rein Therapeutics’ inhaled therapy for idiopathic pulmonary fibrosis (IPF). RENEW (NCT06968845) is ...

GRI Bio has reached an interim enrollment goal for its Phase 2a clinical trial testing GRI-0621 — a therapy targeting natural killer T-cells (NKT cells) to treat idiopathic pulmonary fibrosis (IPF) — ...

A cancer immunotherapy known as ipilimumab was able to reduce scar formation and promote tissue regeneration in the lungs of a mouse model of idiopathic pulmonary fibrosis (IPF). Treatment boosted the ...